CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 92 enrolled
Drug / intervention
Stereotactic body radiotherapy-protonradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01239381
NCT01239381N/ACompleted
CompareCT.gov

Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases

Massachusetts General Hospital·interventional·Posted Nov 11, 2010·Updated Sep 30, 2025

In Brief

A clinical study evaluating Stereotactic body radiotherapy-proton for Solid Tumor and Liver Metastases. Completed, enrolled 92 participants across 2 sites.

Detailed Summary

Stereotactic body radiation therapy (SBRT) is a technique that is used to deliver radiation, to sites in the body. All participants in this study will be treated with SBRT using proton beam radiation. Proton beam radiation uses tiny particles to deliver radiation to tumors. The purpose of this research study is to determine if SBRT with protons will prevent tumor growth and reduce the treatment side effects for liver metastases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Liver Metastases
CountriesUnited States
CollaboratorsDana-Farber Cancer Institute, Brigham and Women's Hospital, National Cancer Institute (NCI)

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2010
Enrollment StartOct 5, 2010
Primary CompletionJan 1, 2016
Study CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 15.6 years ago

Interventions

Stereotactic body radiotherapy-protonradiation

Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks